A pharma ticker's Phase 3 trial hits its primary completion within 90 days. Binary event compresses the time window.
Irrespective of the direction of our failure-probability estimate, the underlying ticker is about to experience a binary event. Implied volatility on the options will be elevated; cash positions will have much wider realised volatility than normal over the next quarter.
Binary clinical trials produce roughly bimodal return distributions — ±30-50% moves clustered around the readout date with little middle ground. This pattern flags the narrow window so interval widths and position sizes reflect the compressed time-to-decision.
Readouts slip. Initial primary completion dates miss by a median of 2-3 months; some trials miss by years. Use the NCT identifier to cross-check ClinicalTrials.gov for the latest trial status update before acting on the catalyst timing.